Literature DB >> 2765638

Design of two-phase prevalence surveys of rare disorders.

P E Shrout1, S C Newman.   

Abstract

Two-phase medical surveys, in which a large sample is assessed with an inexpensive screening instrument and a subsample is selected for a more thorough diagnostic evaluation, appear to have great merit in the epidemiologic study of certain rare disorders. We present the optimal design of two-phase surveys when resources are fixed and when 100% of those screened positive in the first phase must be included in the second-phase evaluation. We go on to examine the relative efficiency of this two-phase design compared to a single-phase design in which all resources are used in a survey that employs the diagnostic evaluation. Given information on the accuracy of the screen and the prevalence of the disorder, the utility of the two-phase design depends on the relative cost of the screening to the diagnostic assessments.

Mesh:

Year:  1989        PMID: 2765638

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  18 in total

1.  Estimating Confidence Intervals and Sampling Proportions in Two-Stage Prevalence Designs.

Authors:  Blase Gambino
Journal:  J Gambl Stud       Date:  1999

2.  Clinical calibration of DSM-IV diagnoses in the World Mental Health (WMH) version of the World Health Organization (WHO) Composite International Diagnostic Interview (WMHCIDI).

Authors:  Ronald C Kessler; Jamie Abelson; Olga Demler; Javier I Escobar; Miriam Gibbon; Margaret E Guyer; Mary J Howes; Robert Jin; William A Vega; Ellen E Walters; Philip Wang; Alan Zaslavsky; Hui Zheng
Journal:  Int J Methods Psychiatr Res       Date:  2004       Impact factor: 4.035

3.  Longitudinal Assessment of Manic Symptoms (LAMS) study: background, design, and initial screening results.

Authors:  Sarah McCue Horwitz; Christine A Demeter; Maria E Pagano; Eric A Youngstrom; Mary A Fristad; L Eugene Arnold; Boris Birmaher; Mary Kay Gill; David Axelson; Robert A Kowatch; Thomas W Frazier; Robert L Findling
Journal:  J Clin Psychiatry       Date:  2010-10-05       Impact factor: 4.384

4.  Issues in Estimating Rates of Pediatric Chronic Fatigue Syndrome and Myalgic Encephalomyelitis in a Community-based Sample.

Authors:  Leonard A Jason; Ben Z Katz; Cynthia Mears; Rachel Jantke; Abby Brown; Madison Sunnquist; Kelly O'Connor
Journal:  Avicenna J Neuropsychophysiol       Date:  2015-11-21

5.  A Novel Application of a Bivariate Regression Model for Binary and Continuous Outcomes to Studies of Fetal Toxicity.

Authors:  Julie S Najita; Yi Li; Paul J Catalano
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2009-09-01       Impact factor: 1.864

6.  On determining the BMD from multiple outcomes in developmental toxicity studies when one outcome is intentionally missing.

Authors:  Julie S Najita; Paul J Catalano
Journal:  Risk Anal       Date:  2012-12-12       Impact factor: 4.000

7.  osDesign: An R Package for the Analysis, Evaluation, and Design of Two-Phase and Case-Control Studies.

Authors:  Sebastien Haneuse; Takumi Saegusa; Thomas Lumley
Journal:  J Stat Softw       Date:  2011-08       Impact factor: 6.440

8.  The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Lenard Adler; Russell Barkley; Joseph Biederman; C Keith Conners; Olga Demler; Stephen V Faraone; Laurence L Greenhill; Mary J Howes; Kristina Secnik; Thomas Spencer; T Bedirhan Ustun; Ellen E Walters; Alan M Zaslavsky
Journal:  Am J Psychiatry       Date:  2006-04       Impact factor: 18.112

9.  Missing Data in Longitudinal Clinical Trials Part A: Design and Conceptual Issues.

Authors:  Philip W Lavori; C Hendricks Brown; Naihua Duan; Robert D Gibbons; Joel Greenhouse
Journal:  Psychiatr Ann       Date:  2008-12-01

10.  The ten questions screen for childhood disabilities: its uses and limitations in Pakistan.

Authors:  M S Durkin; Z M Hasan; K Z Hasan
Journal:  J Epidemiol Community Health       Date:  1995-08       Impact factor: 3.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.